ESLA – estrella immunopharma, inc. (US:NASDAQ)
Stock Stats
News
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at Wall Str
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at Wall Str
Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
Form 8-K Estrella Immunopharma, For: Dec 04
Form 10-Q Estrella Immunopharma, For: Sep 30
Form 8-K Estrella Immunopharma, For: Nov 03
Form 3 Estrella Immunopharma, For: Sep 22 Filed by: Jia Dengyao
Form 8-K Estrella Immunopharma, For: Sep 23
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.